Genomic analysis of autopsy and liquid biopsy in paired patients with metastatic castration resistant prostate cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09431
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Sapporo Medical University
• Principal Investigator: Masumori Naoya 札幌医科大学, 医学部, 教授 (20295356)
• Co-Investigator(Kenkyū-buntansha): 橋本 浩平 札幌医科大学, 医学部, 講師 (40404678) ; 田端 秀敏 札幌医科大学, 医学部, 研究員 (40810586)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 去勢抵抗性前立腺癌 / リキッドバイオプシー / 病理解剖 / 遺伝子パネル

Outline of Final Research Achievements

The aim of this study was to investigate the relationship between gene expression involved in the progression of prostate cancer in the prostate and each metastatic organ, and the response to treatment. Nine patients with metastatic castration-resistant prostate cancer (mCRPC) underwent autopsy and tissue was obtained from the prostate and all metastatic organs. Five of these cases underwent genomic analysis using next-generation sequencing. In cases where the response to treatment was poor,we observed that the expression of genes involved in the cancer progression and cancer suppressor genes was renewed, indicating that there was a possibility that the mutated genes of cancer suppressor genes were amplified. We plan to analyze whether it is possible to predict the progression of mCRPC using liquid biopsy.

Free Research Field

去勢抵抗性前立腺癌

Academic Significance and Societal Importance of the Research Achievements

今回の研究でCRPCの進展様式に関わる遺伝子異常が明らかとなり、生前の血中のcell free DNAのliquid biopsyによってその遺伝子異常が同定できれば、CRPCの進展様式が予測できることとなる。それらを標的とした全く新しい治療法の開発への発展や、局所進展を予測し、局所進展によるイベント発生を未然に防ぐ治療方針をたてることが可能となる。